{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-267402","form_type":"8-K","ticker":"AARD","cik":"0001774857","company_name":"Aardvark Therapeutics, Inc.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.394332+00:00","generated_at":"2026-05-16T23:53:46.687844+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"low","headline":"Aardvark Therapeutics reviews ARD-101 and ARD-201 programs at investor webinar; no new data disclosed","bullets":["Filed presentation lacks specific clinical results or financial figures.","Webinar covered ARD-101 and ARD-201 programs and ObesityWeek 2025 presentations.","Materiality is limited as filing is a procedural update without substantive new information."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-267402","json":"https://secwatch.observer/filing/0001193125-25-267402.json","markdown":"https://secwatch.observer/filing/0001193125-25-267402.md","text":"https://secwatch.observer/filing/0001193125-25-267402.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1774857/000119312525267402/0001193125-25-267402-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1774857/000119312525267402/ck0001774857-20251105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:53:46.687844+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}